title: Targeted Treatment of Esophagogastric Cancer.
abstract: Adenocarcinoma of the esophagogastric junction (EGJ) and stomach remains one of the most common causes of cancer-related death worldwide. Although there is increasing data on the mutational landscape of esophagogastric cancer, phase III trials often yield negative results, and there is a paucity of approved targeted agents. For the time being, the subset of patients carrying HER2-positive metastatic tumors can receive trastuzumab in addition to chemotherapy. Furthermore, ramucirumab has been found to be active both as a single agent and in combination with paclitaxel. Herein, we give an overview of currently approved targeted treatments for locally advanced/resectable as well as unresectable/metastatic EGJ/gastric adenocarcinoma, summarizing the underlying clinical studies. Moreover, further potential targets still under investigation are presented.
authors.affiliation: Department of Oncology and Hematology, Eberhard Karls University, Tübingen, Germany.
authors.forename: Hans-Georg
authors.initials: HG
authors.lastname: Kopp
authors.forename: Ralf-Dieter
authors.initials: RD
authors.lastname: Hofheinz
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000276:immunology; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000276:immunology; D004938:Esophageal Neoplasms / Q000188:drug therapy* / Q000276:immunology*; D004943:Esophagogastric Junction / Q000187:drug effects / Q000276:immunology; D019317:Evidence-Based Medicine; D006801:Humans; D058990:Molecular Targeted Therapy / Q000639:trends*; D009363:Neoplasm Proteins / Q000276:immunology*; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000276:immunology*; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D009363:Neoplasm Proteins